Research Programs
Clinical Research
The Spence Family Synovial Sarcoma Foundation is driving groundbreaking research at the Children’s Hospital of Philadelphia (CHOP) in collaboration with Penn Medicine. This research, led by Dr. Theodore Laetsch is focused on developing innovative treatments for both children and adults with synovial sarcoma by leveraging cutting-edge laboratory models and emerging therapies.
By using a combination of patient-derived tumor samples, live mouse models (PDX), and advanced 3D organoid models, the team is identifying promising new treatments and refining personalized therapeutic strategies.
Targeting the RALDH Enzyme: Testing FDA-approved and experimental drugs designed to block the RALDH enzyme, which prevents cancer cell death. If successful, one of these treatments may enter clinical trials within the next 18 months.
Patient-Derived Xenografts (PDX): Growing synovial sarcoma tumors in the lab and transplanting patient tumor samples into mice to test treatment responses in a model that closely mimics human disease.
Genetic & Epigenetic Research: Identifying critical genetic and epigenetic features of synovial sarcoma to uncover new drug targets and better understand tumor growth mechanisms.
Beyond laboratory studies, the team is actively exploring next-generation immunotherapies and targeted drugs that address the specific vulnerabilities of synovial sarcoma:
TCR T-Cell Therapy: CHOP is participating in trials of T-cell receptor (TCR) therapy, which has shown promising results in targeting synovial sarcoma cells. These engineered immune cells are designed to recognize and attack cancer with greater precision.
Precision Medicine Approaches:
Investigating targeted therapies that exploit the tumor’s genetic and molecular weaknesses to develop more effective, less toxic treatments.
New clinical trials: Ongoing studies, including TCR therapies and epigenetic inhibitors, aim to provide improved treatment options, particularly for patients with advanced or relapsed disease.
Expanding research collaborations: Through partnerships with Penn Medicine and other leading institutions, CHOP researchers are working to accelerate the development of breakthrough therapies.
A focus on both pediatric & adult care: The goal is to develop effective therapies for patients of all ages, ensuring that children, adolescents, and adults benefit from the latest advancements in synovial sarcoma treatment.